Data Insights
                                    By  Company Name
                                
                                No Filter Selected
                                    By  Disease Name
                                
                                No Filter Selected
                                    By  Drug Name
                                
                                No Filter Selected
                                    By Themes
                                
                                No Filter Selected
                                    Showing 1 results out of 1                                
                                
                                                Data Insights
                                                
                                        ION-283 by Ionis Pharmaceuticals for Lafora Disease (Unverricht Disease): Likelihood of Approval
ION-283 is under clinical development by Ionis Pharmaceuticals and currently in Phase II for Lafora Disease (Unverricht Disease). According to...